Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Should be nearing conclusion of the Shoppers Drug Mart cannabis blockchain trial. No news yet.
TTTSF up 67%.
TTTSF: Kaboom, finally.
TTTSF moving on this news, I think.
Though not mentioned, we know TTTSF's Strain Secure is powering the Shoppers Drug trial.
https://www.globenewswire.com/news-release/2020/12/23/2149942/0/en/Avicanna-to-Expand-Access-to-Its-Advanced-and-Evidence-Based-RHO-Phyto-Medical-Products-Through-Provincial-Retailers-Across-Canada.html?fbclid=IwAR0yYNMNjjHMkNGaYiqe5BSeMiWC7qFaq6dOZ-9blQ3k6_Uo_YKpoczdGcw
TTTSF: Low volume wake up on this news.
Link back for more info.
Though not mentioned in article, StrainSecure is TTTSF's blockchain product that is powering this project with Shoppers Drugs. Many more pot companies are involved in the trial, which should be close to concluding.
https://www.globenewswire.com/news-release/2020/12/23/2149942/0/en/Avicanna-to-Expand-Access-to-Its-Advanced-and-Evidence-Based-RHO-Phyto-Medical-Products-Through-Provincial-Retailers-Across-Canada.html
TruTrace Technologies posts FY2020 revenue bump, slimmer loss
https://www.proactiveinvestors.com/companies/news/931365/trutrace-technologies-posts-fy2020-revenue-bump-slimmer-loss-931365.html
TruTrace sales momentum builds on cannabis contracts
https://www.securingindustry.com/pharmaceuticals/trutrace-gathers-sales-momentum-on-cannabis-contracts/s40/a12424/#.X4fkCy2ZNPM
Fins for last Quarter coming AH.
TTTSF: Fins are out.
Guessing it's because they failed to file financials?
What is the difference between a "trading halt", a "Cease Trade Order", a "suspension" or a "business halt"?
A trading halt is issued to suspend trading in a security while material news from the company is disseminated. Halts are usually temporary - less than two hours - with trading resuming once the company has issued the important news. Halts and resumptions are issued by IIROC or a marketplace upon which the security is listed or quoted.
A Cease Trade Order (CTO) is issued against a company for a variety of reasons including failing to meet its disclosure requirements such as filing a quarterly or annual financial statement, or as a result of an enforcement action that involves an investigation of wrongdoing. A CTO is often in place for an extended period of time and can be indefinite. CTOs are issued by the Securities Commissions.
Suspensions are implemented by listing exchanges and generally are a precursor to eventual delisting. Reasons for a suspension include failure to maintain listing requirements.
A business halt, also known as an exchange halt, is implemented by a listing exchange, however in most cases it is expected that the stock will resume trading. Reasons for a business halt include a company undergoing a corporate transaction such as a reverse takeover (RTO) or an interruption in trading caused by system issues.
TTTSF:CSE Bulletin: Suspensions
5:04 PM ET 10/8/20 | Dow Jones
https://www.newsfilecorp.com/release/65564/CSE-Bulletin-Suspensions
Toronto, Ontario--(Newsfile Corp. - le 8 octobre/October 2020) - Effective immediately, the following companies are suspended pursuant to CSE Policy 3. The suspensions are considered Regulatory Halts as defined in National Instrument 23-101 Trading Rules. Cease Trade Orders have been issued by one or more securities commissions.
For more information about Cease Trade Orders, visit the Canadian Securities Administrators Cease Trade Order database at www.securities-administrators.ca
From today's Sedar filing:
The challenges posed by COVID-19 and the subsequent delay in the filing of the Annual Filings have resulted in a delay in the finalization and filing of the Quarterly Filings. However, the Company's board of directors and its management confirm that they are working expeditiously to meet the Company's obligations relating to the filing of the Quarterly Filings. At this time, the Company anticipates being able to complete the Quarterly Filings on or before November 13, 2020.
NXT Water Officially Launches AKESO Hemp Powered Hydration in Conjunction with New Management, Investment Capital and Distribution
https://www.bevnet.com/news/2020/nxt-water-officially-launches-akeso-hemp-powered-hydration-in-conjunction-with-new-management-investment-capital-and-distribution/
TTTSF: TruTrace Technologies Inc. Announces Postponement in Filing of Annual Filings
Toronto, Ontario – August 28, 2020, TruTrace Technologies Inc. (CSE: TTT; OTCQB: TTTSF) (“TruTrace” or the “Company”), creator of a fully-integrated blockchain platform that registers and tracks intellectual property for the cannabis industry announces that it will not be in a position to file its audited annual financial statements for the fiscal year ended April 30, 2020 and the related management's discussion and analysis, as required by Part 4 and Part 5 of National Instrument 51-102: Continuous Disclosure Obligations (collectively, the "Annual Filings") by the filing deadline of August 28, 2020.
This news release is being issued in accordance with the blanket relief of a 45-day extension, provided by Canadian Securities Administrators and Ontario Instrument 51-502: Temporary Exemption from Certain Corporate Finance Requirements, for periodic filings normally required to be made by issuers.
In response to recent proclamations from Canadian health authorities and the challenges resulting from the COVID-19 pandemic, the Company has taken the necessary precautions to protect the health and safety of its employees and the public. Accordingly, a significant portion of the Company's staff as well as its auditor's staff have been working from home, and travel for in-person meetings has been curtailed. While working remotely, the coordination of tasks and work product has been more difficult, the completion of audit procedures due to limited access to paper-based supporting evidence has been delayed, and the entire audit process has been slowed. Furthermore, since the Company's various suppliers and clients have also been working remotely, their responses to standard audit inquiries have slowed, including responses from significant Company clients.
The challenges posed by COVID-19 have resulted in a delay in the finalization and filing of the Annual Filings. However, the Company's board of directors and its management confirm that they are working expeditiously to meet the Company's obligations relating to the filing of the Annual Filings. At this time, the Company anticipates being able to complete the Annual Filings on or before October 12, 2020.
The Company confirms that its management and other insiders are subject to an insider trading black-out policy that reflects the principles in section 9 of National Policy 1 1-207: Failure-to-File Cease Trade Orders and Revocations in Multiple Jurisdictions, such that they are in a black-out period until the end of the second trading day after the Annual Filings have been disclosed by way of a news release.
Since March 27, 2020, the date of filing of the Company’s unaudited interim financial statements for the three months ended January 31, 2020, the Company has announced:
On June 26, 2020, the Company announced that it settled CAD $950,000 of indebtedness previously owed to Heated Details, Inc., the primary vendor responsible for software development, design and maintenance of the Company’s proprietary StrainSecure™ platform and thereby securing all rights to TruTrace’s intellectual property.
On July 3, 2020, the Company announced it signed a software license agreement with OrionOne Global, Inc., a global supply chain provider delivering best-in-class technology which serves as a logistics and tracking smart-hub for navigating shipments and logistics worldwide.
On July 3, 2020, the Company announced the acquisition, by way of private transactions, of control and direction over an aggregate of 17,200,000 common shares in the capital of the Company by Thomas Stephenson, Chief Technology Office of the Company.
On August, 14, 2020, the Company advised the Security Holders that the Annual General and Special Meeting of the Company is to be held on October 16, 2020
On August 25, 2020, the Company announced that it teamed with Riviera & West One Logistics to ensure the highest quality for its line of products including Hygen-X™ hand and surface sanitizer products.
On August 26, 2020, the Company announced that medical distributor, Safe Company selected the TruTrace Enterprise™ SaaS platform to manage inventory and quality assurance processes for its medical and protective consumables, hospital supplies and air purification solutions.
The Canadian Securities Exchange has not reviewed this news release and does not accept responsibility for the adequacy or accuracy of this news release.
On behalf of the Board of Directors: Robert Galarza, Chief Executive Officer and DirectorFor More Information: Robert Galarza, Chief Executive Officer and Director, 888-775-4888
Disclaimer for Forward-Looking Information This news release contains forward-looking information that involves various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company. Forward-looking statements made in this news release relate to the anticipated timing of the Annual Filings. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including adverse market conditions. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this
notice. The Company disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities la
Even a glimmer of hope in the fins would please me. I know we're both checking Sedar every day for the filing!
Interesting. Put 2K order in with limit at Ask of .053. Filled at .04665. Have placed a few orders in last few weeks and they always fill well below the Ask.
GAN up 9% on PENN news.
Fins coming AH today.
GAN Launches Major New Client: Penn Interactive
7:00 AM ET 8/20/20 | BusinessWire
LONDON--(BUSINESS WIRE)--August 20, 2020--
GAN Limited (the "Company" or "GAN") (NASDAQ: GAN), a leading business-to-business supplier of internet gaming software-as-a-service solutions primarily to the U.S. land-based casino industry, today announces the launch of the mychoice(R) social casino app, powered by GAN's Simulated Gaming software and delivered to Penn Interactive, a subsidiary of Penn National Gaming, Inc. ("Penn National") (together "Client"). Simulated Gaming is a core offering of GAN, which enables casino operators to provide social gaming offerings to players in states in advance of real money iGaming, providing meaningful marketing and revenue opportunities for both operators and GAN.
Penn National is the largest single casino operator in the United States to select GAN as its enterprise software service provider of B2B social gaming. The mychoice(R) social casino app, which launched today, will be fully integrated with Penn National's mychoice(R) player loyalty program, which currently has over 20 million members.
Penn Interactive, a wholly owned subsidiary of Penn National Gaming, operates retail sports betting, online social casino, bingo and iCasino products across Penn National's industry leading portfolio of 41 properties in 19 states. Together with Penn National's properties, Simulated Gaming will now be served to casino patrons of more than 100 individual casino properties coast to coast in the U.S. The Client is the 17(th) U.S. casino operator to license GAN's specialist software, which permits patrons to link reward cards to their online Simulated Gaming account and receive reward points automatically triggered by the patrons' diverse online activities.
Jeff Berman, Chief Commercial Officer of GAN, commented:
"We are proud to have been selected by a genuine giant of gaming to upgrade their long-standing B2B social casino offering with a uniquely diverse Simulated Gaming content portfolio accessed via an enhanced custom front-end development and a full integration into Penn National's market leading reward program, leveraging our unique patented technical capability to deliver on-property to online convergence for their carded patrons. We hope this marks the beginning of a partnership that may grow beyond the opportunity of Social Gaming for GAN."
Jon Kaplowitz, Head of Penn Interactive, commented:
"The combination of GAN's great team and proven ability to deliver quality products makes them an ideal partner for Penn. Our mychoice(R) social casino app will be a fun, free-to-play casino experience, and will allow our mychoice(R) members to continue to earn valuable loyalty points from the comfort of their homes."
garettf, has Rob followed any of the APHA folks? They haven't announced participation in the Trial, though they were original members last year when this project started. Wondering because of this article: https://www.prnewswire.com/news-releases/aphria-inc-announces-strategic-supply-agreement-with-canndoc-301105647.html
Only difference between this meeting and the filing for the one last year is:
Issuer sending proxy related materials directly to NOBO: yes.
There were no proxy materials last year.
GAN (22.72) PR's Cordish "PlayLive!" launch.
Moving pre-market.
Financials coming Wednesday.
GAN Launches Real Money Internet Gambling in Pennsylvania for Cordish Gaming Group
August 17 2020 - 07:00AM
GAN Limited (the “Company” or “GAN”) (NASDAQ: GAN), a leading business-to-business supplier of internet gambling software-as-a-service solutions to the U.S. land-based casino industry, today announced the launch of the new “PlayLive!” branded Internet gambling business in the Commonwealth of Pennsylvania for Cordish Gaming Group (“Cordish”), the gaming division of The Cordish Companies.
GAN successfully deployed the real money gaming operation in just 72 days following the execution of a definitive agreement, once again validating GAN’s rapid delivery process. This launch, which leverages the “Live! Rewards” customer rewards program, enables residents of Pennsylvania to enroll in advance, online, for their Live! Rewards Players Card and engage with a full range of gambling content including Internet slots, table games and non-traditional online gambling games. This launch comes ahead of two new Live!-branded gaming facilities in Pittsburgh and Philadelphia, expected to open in late 2020 and early 2021, respectively.
Live! is an existing client of GAN’s Simulated Gaming, which launched online in 2015 as an amenity complementing the Live! Casino & Hotel at Arundel Mills in Hanover, Maryland, and is GAN’s third client of real money Internet gambling enterprise software in the State of Pennsylvania.
Dermot Smurfit, CEO of GAN Limited, stated:
“We are pleased to have launched ‘PlayLive!’ on behalf of Cordish, one of the nation’s leading casino and entertainment companies and an existing GAN client, and look forward to continuing to support the growth of their business by providing a seamless and entertaining online experience for their users.”
About GAN Limited
GAN is a leading business-to-business supplier of internet gambling software-as-a-service solutions to the U.S. land-based casino industry. GAN has developed a proprietary internet gambling enterprise software system, GameSTACK™, which it licenses principally to land-based U.S. casino operators as a turnkey technology solution for regulated real-money internet gambling, encompassing internet gaming, internet sports gaming and virtual Simulated Gaming.
Forward-Looking Statements
This press release contains forward-looking statements that are subject to the safe harbors created under federal securities laws. Words such as “anticipate,” “believe,” “expect,” “intend,” “may,” “will,” and similar expressions are intended to identify forward-looking statements. The forward-looking statements in this press release include statements about the Company’s expectations regarding the closing of its proposed initial public offering and the anticipated use of proceeds from the offering. These statements involve risks, estimates, assumptions and uncertainties that could cause actual results to differ materially from those expressed in these statements, including, among others, risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed offering, as well as risks and uncertainties associated with the Company’s business and finances in general. Because the risks, estimates, assumptions and uncertainties referred to above could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements, readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date on which they are made. The Company undertakes no obligation to update or revise any forward-looking statements for any reason, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200817005126/en/
Investor Contacts:
GAN
Jack Wielebinski
Head of Investor Relations
(214) 799-4660
jwielebinski@GAN.com
The Equity Group
Adam Prior
(212) 371-8660
aprior@equityny.com
Carolyne Sohn
(415) 568-2255
csohn@equityny.com
GAN Launches Real Money Internet Gambling in Pennsylvania for Cordish Gaming Group
LONDON
8/17/2020
GAN Limited (the “Company” or “GAN”) (NASDAQ: GAN), a leading business-to-business supplier of internet gambling software-as-a-service solutions to the U.S. land-based casino industry, today announced the launch of the new “PlayLive!” branded Internet gambling business in the Commonwealth of Pennsylvania for Cordish Gaming Group (“Cordish”), the gaming division of The Cordish Companies.
GAN successfully deployed the real money gaming operation in just 72 days following the execution of a definitive agreement, once again validating GAN’s rapid delivery process. This launch, which leverages the “Live! Rewards” customer rewards program, enables residents of Pennsylvania to enroll in advance, online, for their Live! Rewards Players Card and engage with a full range of gambling content including Internet slots, table games and non-traditional online gambling games. This launch comes ahead of two new Live!-branded gaming facilities in Pittsburgh and Philadelphia, expected to open in late 2020 and early 2021, respectively.
Live! is an existing client of GAN’s Simulated Gaming, which launched online in 2015 as an amenity complementing the Live! Casino & Hotel at Arundel Mills in Hanover, Maryland, and is GAN’s third client of real money Internet gambling enterprise software in the State of Pennsylvania.
Dermot Smurfit, CEO of GAN Limited, stated:
“We are pleased to have launched ‘PlayLive!’ on behalf of Cordish, one of the nation’s leading casino and entertainment companies and an existing GAN client, and look forward to continuing to support the growth of their business by providing a seamless and entertaining online experience for their users.”
About GAN Limited
GAN is a leading business-to-business supplier of internet gambling software-as-a-service solutions to the U.S. land-based casino industry. GAN has developed a proprietary internet gambling enterprise software system, GameSTACK™, which it licenses principally to land-based U.S. casino operators as a turnkey technology solution for regulated real-money internet gambling, encompassing internet gaming, internet sports gaming and virtual Simulated Gaming.
Forward-Looking Statements
This press release contains forward-looking statements that are subject to the safe harbors created under federal securities laws. Words such as “anticipate,” “believe,” “expect,” “intend,” “may,” “will,” and similar expressions are intended to identify forward-looking statements. The forward-looking statements in this press release include statements about the Company’s expectations regarding the closing of its proposed initial public offering and the anticipated use of proceeds from the offering. These statements involve risks, estimates, assumptions and uncertainties that could cause actual results to differ materially from those expressed in these statements, including, among others, risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed offering, as well as risks and uncertainties associated with the Company’s business and finances in general. Because the risks, estimates, assumptions and uncertainties referred to above could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements, readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date on which they are made. The Company undertakes no obligation to update or revise any forward-looking statements for any reason, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200817005126/en/
Investor Contacts:
GAN
Jack Wielebinski
Head of Investor Relations
(214) 799-4660
jwielebinski@GAN.com
The Equity Group
Adam Prior
(212) 371-8660
aprior@equityny.com
Carolyne Sohn
(415) 568-2255
csohn@equityny.com
Copyright Business Wire 2020
News Provided by Business Wire via QuoteMedia
GAN run just starting. Pockets loaded with ITM calls.
Fins next Thursday.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=157588413
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=157586126
GAN client FanDuel the big winner in NJ July online gaming receipts.
Churchill Downs Readying For BetAmerica Switch To GAN, Kambi Software
https://www.onlinepokerreport.com/42921/betamerica-gan-kambi-sports-betting/
Churchill Downs Readying For BetAmerica Switch To GAN, Kambi Software
Brad Allen Posted on Jun 26, 2020 05:49 PDT
BetAmerica GAN Kambi
Churchill Downs has a provisional agreement in place to move its BetAmerica online gambling brand onto a GAN platform and a Kambi sportsbook.
GAN noted in its Q1 earnings call this month it has secured an “agreement in principle” for a “Tier 1” client to move onto its GameStack platform. Online Poker Report understands that client to be Churchill Downs, though the deal is not yet signed and may still be subject to change.
GAN would provide the wider player account management (PAM) platform, and Kambi the sportsbook technology within that.
Both companies declined to comment.
A fresh start for BetAmerica
Churchill Downs previously used the SBTech platform and sportsbook for its BetAmerica brand. However the brand has made relatively limited headway to date in New Jersey and Pennsylvania.
It also suffered a multi-week outage in April.
SBTech is furthermore owned by DraftKings now, meaning any growth from BetAmerica would also benefit a rival operator.
Churchill Downs and DraftKings also declined to comment.
GAN predicts big things for its ‘Tier 1’ client
At its Q1 earnings call, GAN said the incoming Tier 1 client could generate $300-400 million in annual revenue within three years.
“We’ve been working on this deal for an extended period of time,” said CEO Dermot Smurfit during the presentation. “We’re already burning calories and procuring the necessary infrastructure and getting ready to deploy, but we look forward to updating you and everybody else at the right time.”
Smurfit also said the deal would displace an existing US B2B provider, and the new product could be deployed in Michigan, Tennessee, and Illinois.
Churchill Downs’ footprint matches that description, prompting speculation from investors.
GAN (19.92): PlayLive! Casino Comes to Life Online Ahead of Land-Based Live! Casinos in Pennsylvania
https://www.playpennsylvania.com/live-online-casino-app-pa-ahead-of-retail/
PlayLive! Casino has arrived in Pennsylvania months ahead of its brick-and-mortar counterparts. The newest PA online casino will conduct a mandated three-day soft launch on Tuesday, 2 p.m.-midnight, Wednesday 2-midnight and Thursday 12-midnight.
Pending the completion of the test phase and Pennsylvania Gaming Control Board approval, the site will operate 24/7 starting Friday, Aug. 14.
Live! online casino app is available on Android and desktop at playlive.com. However it is not yet available in the App Store for iOS.
An iGaming platform coming before the physical casino is a first. The Cordish Gaming Group plans to open Live! Casino Philadelphia and a mini-casino in Westmoreland, PA in 2021.
PlayLive! Casino offerings at launch
The addition of PlayLive! makes PA home to eleven online casinos. To start, it didn’t waste time presenting a substantial (for Pennsylvania) library of games.
GAN and Cordish in PA
In May 2020, GAN announced that Cordish Group chose them to supply the software platform for their new PlayLive! online casino in Pennsylvania. At the time, the anticipated arrival was Fall 2020.
Dermot Smurfit, CEO of GAN commented:
“Bringing Pennsylvania’s newest casino online later this year will be a genuine privilege, and we look forward to supporting their on-property gaming business by leveraging our U.S. patented iBridge Framework, bridging the Internet gambling experience with that of retail gaming. Online will remain the growth driver of this Industry for decades to come, not just in Pennsylvania but across the nation.”
In the still-early stages of the pandemic in May, Cordish seemed to have an eye on blending the online/in-person gaming experience.
Robert J. Norton, President of Cordish Gaming Group said:
“With our established relationship, GAN was the logical provider of our enterprise platform for launching real money Internet gambling and offers Cordish the ability to extend on-property rewards into the online channel, which has been shown to increase loyalty amongst players of simulated Gaming.”
LCAHU having another nice day. Must be getting close to lift off.
Still struggling drawing the cube, but if I pass can I continue trading, MWM?
Check out TruTrace (TTTSF) Investor Deck
https://app.hubspot.com/documents/4204231/view/81082560?accessId=12f508
Of special interest: Pages 17, 25 and 27.
Beautiful presentation, garrettf. Thanks.
I'm thinking Shoppers Drug Mart/TruTrace collaboration eventually could lead to blockchain tracking for pharmaceuticals.
This is an old article, but still very relevant.
"How Pharma will soon use Blockchain to track your drugs"
https://www.computerworld.com/article/3439843/how-pharma-will-soon-use-blockchain-to-track-your-drugs.html
LOL, sorry for the double Radient post!
TTTSF(.055) closing in on a run, IMO.
I've been slowly accumulating for almost a year. Sparse, but good, info on the board.
https://twitter.com/trutracetech?lang=en
Radient Technologies Inc. Announces Participation in a Medical Cannabis Study Led by the University Health Network in Partnership with Shoppers Drug Mart
EDMONTON, Alberta, July 17, 2020 (GLOBE NEWSWIRE) -- Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture: RTI; OTCQX: RDDTF), a manufacturer of high quality cannabinoid-based formulations and products, is pleased to announce that bioU products by Radient will be available to patients in the recently announced University Health Networks’ (“UHN”) Medical Cannabis Real-World Evidence Study (“MC-RWE Study”) in partnership with Medical Cannabis by Shoppers. The first-of-its-kind study will involve a nation-wide clinical trial to examine the effects of medical cannabis on pain, sleep and anxiety issues.
Radient developed the bioU brand exclusively for Medical Cannabis by Shoppers and the products have been formulated to meet the highest levels of quality, consistency, and stability. All three oral spray formulations currently available on the Medical Cannabis by Shoppers site will be available to patients enrolled in the MC-RWE Study, providing patients with a variety of options in THC and CBD products in a convenient and standard dose format. As part of the study, all bioU products have undergone additional testing, with results registered on TruTrace Technologies software platform and integrated with the Medical Cannabis by Shoppers.
“Radient strongly believes that consistency, safety and standardization are key elements for all medical products, and are excited to partner with UHN, Shoppers and TruTrace on this groundbreaking study,” said Denis Taschuk, CEO of Radient Technologies. “Providing patients and medical professionals with trusted products that deliver repeatable results is a crucial step in having cannabis incorporated into medical treatments and is at the heart of all Radient products. Shoppers is creating a standard for medical cannabis, which along with the data from these clinical trials, will increase the confidence of both doctors and patients in using cannabis for medical purposes.”
About the UHN MC-RWE Study
Led by UHN's Dr. Hance Clarke, the observational study is targeting a minimum of 2,000 patients who will be followed over a 24-week period. Enrolled patients will have access to certain fully verified products on the Medical Cannabis by Shoppers platform, which have been tested for detailed cannabinoid and terpene profiles. Read more about the study here.
About Radient
Radient Technologies is a commercial manufacturer of high quality cannabinoid based formulations, ingredients and products. Utilizing a proprietary extraction and downstream processing platform that recovers up to 99% of cannabinoids from the cannabis plant, Radient develops specialty products and ingredients that contain a broad range of cannabinoid and terpene profiles while meeting the highest standards of quality and safety. Please visit www.radientinc.com for more information.
SOURCE: Radient Technologies Inc.
For further information please contact:
Radient - Investor Relations
ir@radientinc.com
Forward Looking Information:
This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, without limitation, statements regarding the growth of the Company’s business operations; the Company’s participation in the MC-RWE Study; the Company’s ability to grow its business in the cannabis sector and the Company’s future plans. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Radient, as the case may be, to be materially different from those expressed or implied by such forward-looking information. Although Radient has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. Radient does not undertake to update any forward-looking information, except in accordance with applicable securities laws.
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Related Articles
More articles issued by Radient Technologies Inc
More articles related to:
Company Announcement
The Valens Company to contribute Nüance premium cannabis oil to first-of-its-kind evidence study on patients using medicinal cannabis
https://www.proactiveinvestors.com/companies/news/924048/the-valens-company-to-contribute-nance-premium-cannabis-oil-to-first-of-its-kind-evidence-study-on-patients-using-medicinal-cannabis-924048.html
The Canadian study will look at the therapeutic effects of medical cannabis in adults with chronic pain, sleep problems and anxiety issues
The study uses TruTrace blockchain secure technology of the Medical Cannabis by Shoppers online product portal to test and verify products
The Valens Company Inc (TSE:VLNS) (OTCQX:VLNCF) has said it is participating in a new study on medical cannabis led by the University Health Network and Canadian pharmacy chain Shoppers Drug Mart’s medical cannabis division.
The first of its kind, the real-world evidence study will look at the therapeutic effects of medical cannabis in adults with chronic pain, sleep problems and anxiety issues, and will use TruTrace Technologies Inc (CSE:TTT) (OTCMKTS:TTTSF) blockchain secure technology of the Medical Cannabis by Shoppers online product portal that tests and verifies cannabis products.
Kelowna, BC-based Valens is contributing its Nüance brand of premium cannabis oil to the study, it said in a release.
READ: The Valens Company strikes manufacturing deal with FPS Brands to launch the ufeelu line of hemp-derived CBD products
During the study, Nüance will be tested and verified results on each batch will be available through the Medical Cannabis by Shoppers portal for physicians and patients, who can also identify the contents of their product through the portal.
By identifying the potency levels of THC and CBD, patients can confidently rely on data to ensure consistency throughout batches, Valens noted.
The aim of the study, which is designed by Dr Hance Clarke of Toronto’s University Health Network, is to give physicians, pharmacists and patients more confidence in medicinal cannabis products to treat ailments such as pain, according to Valens.
"Nuance oils are developed exclusively for Shoppers Drug Mart with medical cannabis patients at the core,” Valens CEO Tyler Robson said in the statement.
“To be able to participate in this real-world study and have the opportunity to understand how our products could be used as a treatment is an exciting step in the right direction for us.”
Robson pointed out the firm is looking forward to using insights and data from the study to further advance its commitment to developing and testing the highest-quality and most reliable products for patients using cannabis for both medical purposes as well as recreational consumers.
"Medical Cannabis by Shoppers is best placed to offer Canadians the reassurance of medical products that have been tested and validated," said Ken Weisbrod, vice president business development and cannabis strategy at Shoppers Drug Mart.
"Our development of a blockchain secured initiative with TruTrace has now been integrated into an operational portal that will provide products with an immutable digital identity that can capture everything from detailed chemistry down to its DNA," he added.
The 24-week study will follow around 2,000 participants across Canada.
Contact Angela at angela@proactiveinvestors.com
Follow her on Twitter @AHarmantas
Radient Technologies Inc. Announces Participation in a Medical Cannabis Study Led by the University Health Network in Partnership with Shoppers Drug Mart
https://www.globenewswire.com/news-release/2020/07/17/2063864/0/en/Radient-Technologies-Inc-Announces-Participation-in-a-Medical-Cannabis-Study-Led-by-the-University-Health-Network-in-Partnership-with-Shoppers-Drug-Mart.html
EDMONTON, Alberta, July 17, 2020 (GLOBE NEWSWIRE) -- Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture: RTI; OTCQX: RDDTF), a manufacturer of high quality cannabinoid-based formulations and products, is pleased to announce that bioU products by Radient will be available to patients in the recently announced University Health Networks’ (“UHN”) Medical Cannabis Real-World Evidence Study (“MC-RWE Study”) in partnership with Medical Cannabis by Shoppers. The first-of-its-kind study will involve a nation-wide clinical trial to examine the effects of medical cannabis on pain, sleep and anxiety issues.
Radient developed the bioU brand exclusively for Medical Cannabis by Shoppers and the products have been formulated to meet the highest levels of quality, consistency, and stability. All three oral spray formulations currently available on the Medical Cannabis by Shoppers site will be available to patients enrolled in the MC-RWE Study, providing patients with a variety of options in THC and CBD products in a convenient and standard dose format. As part of the study, all bioU products have undergone additional testing, with results registered on TruTrace Technologies software platform and integrated with the Medical Cannabis by Shoppers.
“Radient strongly believes that consistency, safety and standardization are key elements for all medical products, and are excited to partner with UHN, Shoppers and TruTrace on this groundbreaking study,” said Denis Taschuk, CEO of Radient Technologies. “Providing patients and medical professionals with trusted products that deliver repeatable results is a crucial step in having cannabis incorporated into medical treatments and is at the heart of all Radient products. Shoppers is creating a standard for medical cannabis, which along with the data from these clinical trials, will increase the confidence of both doctors and patients in using cannabis for medical purposes.”
About the UHN MC-RWE Study
Led by UHN's Dr. Hance Clarke, the observational study is targeting a minimum of 2,000 patients who will be followed over a 24-week period. Enrolled patients will have access to certain fully verified products on the Medical Cannabis by Shoppers platform, which have been tested for detailed cannabinoid and terpene profiles. Read more about the study here.
About Radient
Radient Technologies is a commercial manufacturer of high quality cannabinoid based formulations, ingredients and products. Utilizing a proprietary extraction and downstream processing platform that recovers up to 99% of cannabinoids from the cannabis plant, Radient develops specialty products and ingredients that contain a broad range of cannabinoid and terpene profiles while meeting the highest standards of quality and safety. Please visit www.radientinc.com for more information.
SOURCE: Radient Technologies Inc.
For further information please contact:
Radient - Investor Relations
ir@radientinc.com
Forward Looking Information:
This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, without limitation, statements regarding the growth of the Company’s business operations; the Company’s participation in the MC-RWE Study; the Company’s ability to grow its business in the cannabis sector and the Company’s future plans. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Radient, as the case may be, to be materially different from those expressed or implied by such forward-looking information. Although Radient has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. Radient does not undertake to update any forward-looking information, except in accordance with applicable securities laws.
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Related Articles
More articles issued by Radient Technologies Inc
More articles related to:
Company Announcement
MediPharm Labs Selected by University Health Network and Medical Cannabis by Shoppers Inc. for First Real-World Evidence, Patient-Centred Clinical Trial Using Blockchain Technology
https://www.globenewswire.com/news-release/2020/07/16/2063212/0/en/MediPharm-Labs-Selected-by-University-Health-Network-and-Medical-Cannabis-by-Shoppers-Inc-for-First-Real-World-Evidence-Patient-Centred-Clinical-Trial-Using-Blockchain-Technology.html
PR_July 16, 2020
MediPharm Labs is proud to have seven products which are made in its GMP-certified facility selected for inclusion in the Medical Cannabis Real-World Evidence (MC-RWE) Research Study led by the University Health Network in partnership with Medical Cannabis by Shoppers™; the products include: three MediPharm Labs formulated CBD oils plus four spays and formulated oils to be manufactured for Avicanna Inc.
TORONTO, July 16, 2020 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, today announced its participation in a ground-breaking collaboration between University Health Network (“UHN”) and Medical Cannabis by Shoppers Inc. that will use blockchain technology to track medical cannabis products from seed to sale.
MediPharm Labs’ own pharma-quality (GMP Certified) CBD and THC products, including CBD 25, CBD 25:5 and CBD 50, first launched on the Medical Cannabis by Shoppers™ portal earlier this year, as well as a suite of Avicanna Inc's Rho Phyto™ CBD and THC products, manufactured by MediPharm Labs, have been selected to be used in a 24-week observational study targeting at least 2,000 Canadian medical cannabis consumers.
“As part of the largest pharmacy chain in Canada, the Medical Cannabis by Shoppers team is delighted to partner in this research with MediPharm Labs, a trusted name in the cannabis industry and a company with whom we have a strong commercial relationship,” said Ken Weisbrod, Vice President Business Development/Cannabis Strategy, Shoppers Drug Mart. "The success of this research is dependent on collaboration, and with partners like UHN, MediPharm Labs, TruTrace and Shoppers on board, the stage is set for achievement."
The collaboration will use a blockchain-secured software platform – designed by TruTrace Technologies Inc. (CSE: TTT)(OTCQB: TTTSF) (CSE: TTT)(OTCQB: TTTSF) and integrated with the Medical Cannabis by Shoppers portal – to manage, track and trace medical cannabis strains in 7 distinct products manufactured by MediPharm Labs, or about 20% of the study formulary, in various formats including oils and extracts throughout each step of the supply chain.
Robert Galarza, CEO, TruTrace Technologies commented, “The evolution of the medical cannabis industry over the past several years has been nothing short of remarkable and the commitment by MediPharm Labs to implement the highest level of product quality through certified GMP standards and protocols, as well as a desire to advance innovation, collaboration and technology alongside companies like ours will only further drive our industry forward. We are excited to explore how the power of dynamic and transparent data can support their initiatives in Canada and beyond.”
“This important study, conducted by one of the largest health research organizations in Canada, will have wide-reaching benefits for cannabis patients and MediPharm Labs as we remain dedicated to producing pharmaceutical-quality products that are rigorously tested and verified on a lot-by-lot basis using GMP certified standards,” said Pat McCutcheon, Chief Executive Officer, MediPharm Labs. “Our view is that this study has the potential to enhance confidence in medical cannabis by giving physicians and patients true transparency into product chemistry, composition and effectiveness so that they can prescribe validated products and adjust their treatment regimens based on real-world evidence. We are proud to be a contributing partner with leaders in the fields of science, technology, medical dispensary and cannabis who have come together to make this study possible.”
About the UHN Study
This novel Medical Cannabis Real World Evidence study will look to match cannabis genetics, with defined cannabinoid and terpene profiles, to patient outcomes using validated questionnaires and scales. Patients enrolled in this study will have access to a wide range of products that have consistent genetic, chemical, cannabinoid and terpene profiles and will know exactly what is in their products down to the milligram of THC and cannabidiol. If a product in the study is effective for them, they can rely on it being identical, from batch to batch.
From this work, a national repository of real-time data about cannabis products, their composition and their effectiveness will be made available to Medical Cannabis by Shoppers’ patients.
Patients participating in the study will use the same ecommerce platform as other Medical Cannabis by Shoppers patients, though research participants will have access to the first fully verified products. First launched in Ontario in January 2019, Medical Cannabis by Shoppers (a subsidiary of Shoppers Drug Mart) provides patient access to numerous medical cannabis products from over 20 licensed cannabis brands. Cannabis medication can be ordered online or via phone, and is shipped directly and discreetly to their doorstep. The Shoppers Cannabis Care team – a dedicated call center staffed by cannabis-trained advisors and pharmacists - provides counselling and support for patients.
University Health Network consists of Toronto General, recently ranked the #4 Hospital in the World according to Newsweek Magazine, and Toronto Western Hospital, the Princess Margaret Cancer Centre, Toronto Rehabilitation Institute, and the Michener Institute of Education at UHN. The scope of research and complexity of cases at University Health Network has made it a national and international source of discovery, education, and patient care.
Why Traceability Is Important
Medical cannabis currently lacks assigned Drug Identification Numbers (“DINs”) that quantify attributes such as chemistry, genetics, and metabolomics. This information is critical for producers, distributors, government agencies, payers, clinicians, and patients. Maintaining an effective and interoperable traceability ecosystem built on reliable and immutable data provides safe and consistent medicine.
MediPharm Labs distinguishes itself as a supplier of medical cannabis through its GMP-certified production capabilities. This internationally recognized certification is only granted to companies that can demonstrate consistency, precision, and quality in all stages of production and are able to comply with GMP principles for manufacturing Active Pharmaceutical Ingredients and final medicinal products.
About TruTrace Technologies, Inc.
TruTrace (CSE: TTT / OTCQB: TTTSF) is a fully integrated software platform, secured on a blockchain infrastructure that gives clients the ability to store, manage, share and immediately access quality assurance and testing details, COAs, as well as motion and movement intelligence on inventory from batches and lots to serialized items. The platform was specifically designed to power the traceability of testing standards within the medical cannabis, nutraceutical, food and pharmaceutical space with a focus on the authentication of source materials or ingredients used in formulation.
About MediPharm Labs Corp.
Founded in 2015, MediPharm Labs specializes in the production of purified, pharmaceutical quality cannabis oil and concentrates and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard built clean rooms. MediPharm Labs has invested in an expert, research-driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities with five primary extraction lines for delivery of pure, trusted and precision -dosed cannabis products for its customers. Through its wholesale and white label platforms, they formulate, consumer-test, process, package and distribute cannabis extracts and advanced cannabinoid-based products to domestic and international markets. As a global leader, MediPharm Labs has completed commercial exports to Australia and is nearing commercialization of its Australian Extraction facility. MediPharm Labs Australia was established in 2017.
For further information, please contact:
Laura Lepore, VP, Investor Relations
Telephone: 416-913-7425 ext. 1525
Email: investors@medipharmlabs.com
Website: www.medipharmlabs.com
CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION:
This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of MediPharm Labs to obtain adequate financing; the delay or failure to receive regulatory approvals; and other factors discussed in MediPharm Labs’ filings, available on the SEDAR website at www.sedar.com. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm Labs assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/68f0c6dd-6eda-49cc-8112-65a9add9179c.
Thanks, garrettf.
More active on Twitter, too.
https://twitter.com/TruTraceTech
Looks like MM's positioning themselves for run. I noticed that earlier but didn't see the news til now.
TruTrace Technologies Update
2:00 PM ET 7/14/20 | Dow Jones
TruTrace Technologies Update
July 14, 2020 -- (TruTrace Technologies) --
(TheNewswire)July 14, 2020 - TheNewswire - TruTrace Technologies (CNSX:TTT.CN), (OTC:TTTSF) would like to share the following from the desk of the CEO:
Friends:
I hope this letter finds you well and that you are staying safe during these unprecedented times. On behalf of the entire TruTrace Technologies team, I'd like to thank you for your ongoing support and commitment to our organization.
As you know, over the past two years we at TruTrace have been on a path to bring greater transparency and interoperability to the medical cannabis sector. Our mission is aimed squarely at delivering innovative technology to bring visibility and collaboration to this emerging industry. They say nothing worth having comes easy and further, if there is one word that defines every member of our team it is simply...resiliency.
Our resiliency has kept us on track, committed to deliver on time and under budget for our largest client, and our resiliency will never waiver.
Over the past few weeks, we're happy that we've been able to share some exciting news. From securing a strategic partnership with OrionOne Global, which aligns TruTrace with the global freight and logistics space, to a landmark moment for the company and the culmination of countless months of work.
On Thursday, July 9th, the largest health research organization in North America, University Health Network and Canada's largest pharmacy Shoppers Drug Martannounced the launch of a ground-breaking Real-World Evidence study underpinned by our blockchain technology.
Over a year in the making, this deployment represents the real-world implementation of our StrainSecure(TM) platform within the Shoppers ecosystem with an aim to become a fundamental part of legalized medical cannabis for years to come.
We are proud of our accomplishments and grateful to our client/partners at: Aphria, Aurora Cannabis, Avicanna, Inc., CanniMed, Dosecann Solutions, MediPharm Labs, Organigram, Radient Technologies, The Flowr Corporation The Valens Company, WeedMD Rx Inc./Starseed Medicinal Inc. and Zenabis Global, as well our laboratory partners at Sigma Analytical, Anandia Labs and High North.
This is our moment. This is our chance to dig deeper, stay committed to road ahead, stay resilient and continue on a path to achieving our goals.
From my desk to yours, I would like to thank you again for your support.
Best regards,
Robert Galarza
CEO
TruTrace Technologies, Inc.
(CSE: TTT / OTCQB: TTTSF)
info@trutrace.co
844-656-3629
Copyright (c) 2020 TheNewswire - All rights reserved.
> Dow Jones Newswires
July 14, 2020 14:00 ET (18:00 GMT)